Eyelid Myokymia as a presumed manifestation of Coronavirus Disease 2019 (COVID-19)

Abstract Purpose To report the eyelid myokymia in patients recovered from COVID-19 disease. Methods A cohort of 15 patients who developed eyelid myokymia during or immediate post-recovery of systemic disease were evaluated. Demographic, clinical characteristics, effect of age, and hospitalization on the disease course were studied. The disease course was evaluated every month for 3 months period. Results All, except 2, patients had complete resolution of lid myokymia within 3 months of onset. Mean ± SD myokymia recovery time was 44.1 ± 20.9 Days. Gender had no impact on the duration of disease. Age and duration of hospitalization had a strong positive correlation with myokymia recovery time (r = 0.8, p = 0.001 and r = 0.8, p = 0.01). Conclusion Eyelid myokymia may involve COVID-19 patients during or immediately after systemic recovery. While myokymia recovers gradually in all these patients; older age and longer duration of hospitalization are associated with slower recovery.